Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19-Reference-Cited by-同舟云学术

Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19

Published:2021-08-31 Issue:4 Volume:15 Page:205-210
ISSN:1881-7815
Container-title:BioScience Trends
language:en
Short-container-title:BST

Author:

Su Jie¹,Lu Hongzhou²

Affiliation:

1. State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated with the Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, China.

2. Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine,Health (social science)

Link

https://www.jstage.jst.go.jp/article/bst/15/4/15_2021.01227/_pdf

Reference62 articles.

1. 1. Callaway E, Cyranoski D, Mallapaty S, Stoye E, Tollefson J. The coronavirus pandemic in five powerful charts. Nature. 2020; 579:482-483.

2. 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497-506.

3. 3. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020; 583:437-440.

4. 4. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med.2021; 384:795-807.

5. 5. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA. 2020; 324:1048-1057.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alpha and Delta variants and vaccination effectiveness against severity in COVID-19 inpatients based on medical claims in Japan;GHM Open;2023-08-27

2. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity;Frontiers in Immunology;2022-11-30

3. Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents;COVID;2022-05-12

4. Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination;Vaccines;2022-02-11

5. Drug discovery to treat COVID-19 two years after its outbreak;Drug Discoveries & Therapeutics;2021-12-31